Sistemik İsotretinoin Tedavisi Alan Hastalarda Gözyaşı ve Oküler Yüzey Değişiklikleri

Purpose: Our aim in this study was to assess the ocular surface and tear film changes in acne vulgaris patients receiving systemic\udisotretinoin.\udMaterial and Method: Twenty-two eyes of 22 patients who received oral isotretinoin (roaccutane®, 0.7 mg/kg/day) for nodular acne\udvulgaris were enrolled in this prospective study. Tear film break-up time (BUT), Schirmer 1 test scores with anesthesia, ocular surface disease\udindex (OSDI) scores and conjunctival impression cytology scores were recorded before treatment and at 3- and 6-month visits following the\udbeginning of treatment.\udResults: BUT values decreased and OSDI scores significantly increased at 3 months after treatment (p=0.007 and p=0.018, paired samples\udtest). Schirmer scores did not significantly change by isotretinoin treatment. Of 9 eyes with impression cytology specimens, 4 revealed normal\udconjunctival findings before treatment. At the 3rd month, there was an increase in the scores characterized by decrease of Goblet cells, and at 6\udmonths of treatment, normal conjunctival findings did not exist in any of the patients (p=0.004, Friedman test).\udDiscussion: Systemic isotretinoin treatment can cause alterations in the tear film and cause dry eye symptoms. (Turk J Ophthalmol 2013;\ud43: 309-12